medigraphic.com
Instituto Nacional de Salud Pública

2014, Number 5

<< Back

salud publica mex 2014; 56 (5)

Un interrogante para la salud de las mujeres Sustancias químicas en los productos de higiene femenina y en los lubricantes personales

Language: Spanish
References: 55
Page: 562-569
PDF size: 540.35 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Fuchs EJ, et al. Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission. J Infect Dis 195(5):703-710 (2007); Disponible en: http://dx.doi.org/10.1086/511279.

  2. Moench TR, et al. Microbicide excipients can greatly increase susceptibility to genital herpes transmission in the mouse. BMC Infect Dis 10:331(2010); Disponible en: http://dx.doi. org/10.1186/1471-2334-10-331.

  3. Euromonitor International. Country Report: Sanitary Protection in the US. Londres, RU: Euromonitor International (junio de 2013). Disponible en: http://www.euromonitor.com/ sanitary-protection-in-the-us/report [consultado el 24 de enero de 2014].

  4. Scranton A. Chem Fatale: Potential Health Effects of Toxic Chemicals in Feminine Care Products. Missoula, MT: Women’s Voices for the Earth (noviembre de 2013). Disponible en: http://goo.gl/BgIwdu [consultado el 24 de enero de 2014].

  5. H.R. 2332 (112o Congreso): Robin Danielson Act. Disponible en: http://thomas.loc.gov/cgi-bin/ query/z?c112:H.R.2332: [consultado el 24 de enero de 2014].

  6. Cottrell BH. Vaginal douching. J Obstet Gynecol Neonatal Nurs 32(1):12-18 (2003); Disponible en: http://dx.doi. org/10.1177/0884217502239796.

  7. Kumamoto Y, Iwasaki A. Unique features of antiviral immune system of the vaginal mucosa. Curr Opin Immunol 24(4):411-416 (2012); Disponible en: http://dx.doi.org/10.1016/j. coi.2012.05.006.

  8. Keir L, et al. Medical Assisting: Administrative and Clinical Competencies. Clifton Park, NY:Delmar Learning (1998). Disponible en: http://goo.gl/BDGHfg [consultado el 24 de enero de 2014].

  9. Farage M, Maibach HI. The vulvar epithelium differs from the skin: implications for cutaneous testing to address topical vulvar exposures. Contact Dermatitis 51(4):201-209 (2004); Disponible en: http://dx.doi.org/10.1111/j.0105- 1873.2004.00444.x.

  10. Hussain A, Ahsan F. The vagina as a route for systemic drug delivery. J Control Release 103(2):301-313 (2005); Disponible en: http:// dx.doi.org/10.1016/j.jconrel.2004.11.034.

  11. Tourgeman DE, et al. Serum and tissue hormone levels of vaginally and orally administered estradiol. Am J Obstet Gynecol 180(6):1480-1483 (1999); Disponible en: http:// dx.doi.org/10.1016/S0002-9378(99)70042-6.

  12. Kobrosly RW, et al. Socioeconomic factors and phthalate metabolite concentrations among United States women of reproductive age. Environ Res 115:11-17 (2012); Disponible en: http://dx.doi.org/10.1016/j.envres.2012.03.008.

  13. Belova A, et al. A method to screen U.S. environmental biomonitoring data for race/ ethnicity and income-related disparity. Environ Health 12(1):114 (2013); Disponible en: http:// dx.doi.org/10.1186/1476-069X-12-114.

  14. Calafat AM, et al. Urinary concentrations of four parabens in the U.S. population: NHANES 2005–2006. Environ Health Perspect 118(5):679- 685 (2010); Disponible en: http://dx.doi. org/10.1289/ehp.0901560.

  15. Karpuzoglu E, et al. Parabens: potential impact of low-affinity estrogen receptor binding chemicals on human health. J Toxicol Environ Health B Crit Rev 16(5):321-335 (2013); Disponible en: http://dx.doi.org/10.1080/109374 04.2013.809252.

  16. Mankidy R, et al. Biological impact of phthalates. Toxicol Lett 217(1):50-58 (2013); Disponible en: http://dx.doi.org/10.1016/j. toxlet.2012.11.025.

  17. Simmons DBD, et al. Interaction of Galaxolide® with the human and trout estrogen receptor-α. Sci Total Environ 408(24):6158-6154 (2010); Disponible en: http://dx.doi.org/10.1016/j. scitotenv.2010.09.027.

  18. Zhang J, et al. Vaginal douching and adverse health effects: a meta-analysis. Am J Public Health 87(7):1207-1211 (1997); Disponible en: http:// dx.doi.org/10.2105/AJPH.87.7.1207.

  19. Wilson C. Recurrent vulvovaginitis candidiasis: an overview of traditional and alternative therapies. Adv Nurse Pract 13(5):24- 29 (2005); Disponible en: http://www.ncbi.nlm. nih.gov/pubmed/15898312.

  20. Foxman B, et al. Candida vaginitis: selfreported incidence and associated costs. Sex Transm Dis 27(4):230-2355 (2000); Disponible en: http://dx.doi.org/10.1097/00007435- 200004000-00009.

  21. McKee MD, et al. Vaginal douching among Latinas: practices and meaning. Matern Child Health J 13(1):98-106 (2009); Disponible en: http://dx.doi.org/10.1007/s10995-008-0327-3.

  22. APHA. Policy Statement: Vaginal Douching and Adverse Health Outcomes. Washington DC: American Public Health Association (Asociación Americana de Salud Pública, 6 de noviembre de 2007). Disponible en: http://goo.gl/vwTqDk [consultado el 24 de enero de 2014].

  23. OWH. Douching Fact Sheet [página web]. Washington, DC:Office on Women’s Health, U.S. Department of Health and Human Services (Oficina de Salud de las Mujeres, Departamento de salud y Servicios Humanos de Estados Unidosactualizada el 16 de julio de 2012). Disponible en: http://goo.gl/f0zNGR [consultada el 24 de enero de 2014].

  24. Martino JL, Vermund SH. Vaginal douching: evidence for risks or benefits to women’s health. Epidemiol Rev 24(2):109-124 (2002); Disponible en: http://dx.doi.org/10.1093/epirev/mxf004.

  25. Ness RB, et al. Douching and endometritis; results from the PID Evaluation and Clinical Health (PEACH) Study. Sex Transm Dis 28(4):240-245 (2001); Disponible en: http:// dx.doi.org/10.1097/00007435-200104000-00010.

  26. Brown JM, et al. Intravaginal practices and risk of bacterial vaginosis and candidiasis infection among a cohort of women in the United States. Obstet Gynecol 12(4):773-780 (2013); Disponible en: http://dx.doi.org/10.1097/ AOG.0b013e31828786f8.

  27. Angotti LB, et al. Vaginitis: making sense of over-the-counter treatment options. Infect Dis Obstet Gynecol 2007:97424 (2007); Disponible en: http://dx.doi.org/10.1155/2007/97424.

  28. Ferris DG, et al. Women’s use of over-thecounter antifungal medications for gynecologic symptoms. J Fam Pract 42(6):595-600 (1996); Disponible en: http://www.ncbi.nlm.nih.gov/ pubmed/8656170.

  29. Sihvo S, et al. Self-medication with vaginal antifungal drugs: physicians’ experiences and women’s utilization patterns. Fam Pract 17(2):145-149 (2000); Disponible en: http:// dx.doi.org/10.1093/fampra/17.2.145.

  30. McCaig LF, McNeil MM. Trends in prescribing for vulvovaginal candidiasis in the United States. Pharmacoepidemiol Drug Saf 14(2):113-120 (2005); Disponible en: http:// dx.doi.org/10.1002/pds.960.

  31. Bauer A, et al. Allergic contact dermatitis in patients with anogenital complaints. J Reprod Med 45(8):649-654 (2000); Disponible en: http:// www.ncbi.nlm.nih.gov/pubmed/10986683.

  32. Wujanto L, Wakelin S. Allergic contact dermatitis to colophonium in a sanitary pad—an overlooked allergen? Contact Dermatitis 66(3):161-162 (2012); Disponible en: http:// dx.doi.org/10.1111/j.1600-0536.2011.02006.x.

  33. Larsen WG. Sanitary napkin dermatitis due to the perfume. Arch Dermatol 115(3):363 (1979); Disponible en: http://dx.doi.org/10.1001/ archderm.1979.04010030065027.

  34. Eason EL, Feldman P. Contact dermatitis associated with the use of Always sanitary napkins. Can Med Assoc J 154(8):1173-1176 (1996); Disponible en: http://www.ncbi.nlm.nih. gov/pubmed/8612252.

  35. Williams JD, et al. Allergic contact dermatitis from methyldibromo glutaronitrile in a sanitary pad and review of Australian clinic data. Contact Dermatitis 56(3):164-167 (2007); Disponible en: http://dx.doi.org/10.1111/j.1600- 0536.2007.01040.x.

  36. Schlievert PM, et al. Staphylococcus aureus exotoxins are present in vivo in tampons. Clin Vaccine Immunol 17(5):722-727 (2010); Disponible en: http://dx.doi.org/10.1128/ CVI.00483-09.

  37. Tierno Jr. PM, Hanna BA. Ecology of toxic shock syndrome: amplification of toxic shock syndrome toxin 1 by materials of medical interest. Clin Infect Dis 11(suppl 1):S182-S187 (1989); Disponible en: http://dx.doi.org/10.1093/ clinids/11.Supplement_1.S182.

  38. Tierno Jr. PM, Hanna BA. In vitro amplification of toxic shock syndrome toxin-1 by intravaginal devices. Contraception 31(2):185-194 (1985); Disponible en: http://dx.doi.org/10.1016/0010- 7824(85)90033-2.

  39. Tierno Jr. PM, et al. Effects of toxic shock syndrome Staphylococcus aureus, endotoxin and tampons in a mouse model. Clin Invest Med 10(2):64-70 (1987); Disponible en: http://www. ncbi.nlm.nih.gov/pubmed/3581548.

  40. Tierno Jr. PM, Hanna BA. Propensity of tampons and barrier contraceptives to amplify S. aureus toxic shock syndrome toxin-1. Infect Dis Obstet Gynecol 2(3):140-145 (1994); Disponible en: http://dx.doi.org/10.1155%2FS1064744994 000542.

  41. FDA. Tampons and Asbestos, Dioxin, & Toxic Shock Syndrome [página web]. Silver Spring, MD:U.S. Food & Drug Administration (Administración de Alimentos y Medicamentos de Estados Unidos, actualizada el 20 de marzo de 2013). Disponible en: http://goo.gl/gtqgrC [consultada el 24 de enero de 2014].

  42. Weissberg SM, Dodson MG. Recurrent vaginal and cervical ulcers associated with tampon use. JAMA 250(11):1430-1431 (1983); Disponible en: http://dx.doi.org/10.1001/ jama.1983.03340110044031.

  43. U.S. Institute of Medicine. Toxic Shock Syndrome: Assessment of Current Information and Future Research Needs: Report of a Study. Washington, DC: National Academy Press (1982).

  44. Friedrich EG Jr., Siegesmund KA. Tamponassociated vaginal ulcerations. Obstet Gynecol 55(2):149-156 (1980); Disponible en: http://www. ncbi.nlm.nih.gov/pubmed/7352071.

  45. DeVito MJ, Schecter A. Exposure assessment to dioxins from the use of tampons and diapers. Environ Health Perspect 110(1):23-28 (2002); Disponible en: http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC1240689/.

  46. Czerwinski BS. Adult feminine hygiene practices. Appl Nurs Res 9(3):123-129 (1996); Disponible en: http://dx.doi.org/10.1016/S0897- 1897(96)80218-7.

  47. Dezzutti CS, et al. Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity. PLoS One 7(11):e48328 (2012); Disponible en: http:// dx.doi.org/10.1371/journal.pone.0048328.

  48. Wolf LK. Studies raise questions about safety of personal lubricants. Chem Eng News 90(50):46-47 (2012); Disponible en: http://cen. acs.org/articles/90/i50/Studies-Raise-Questions- Safety-Personal.html.

  49. Gorbach PM, et al. The slippery slope: lubricant use and rectal sexually transmitted infections: a newly identified risk. Sex Transm Dis 29(1):59-64 (2012); Disponible en: http:// dx.doi.org/10.1097/OLQ.0b013e318235502b.

  50. Brotman RM, et al. Rapid fluctuation of the vaginal microbiota measured by Gram stain analysis. Sex Transm Infect 86(4):297-302 (2010); Disponible en: http://dx.doi.org/10.1136/ sti.2009.040592.

  51. Schlievert PM, et al. Glycerol monolaurate does not alter rhesus macaque (Macaca mulatta) vaginal lactobacilli and is safe for chronic use. Antimicrob Agents Chemother 51(12):4448- 4444 (2008); Disponible en: http://dx.doi. org/10.1128/AAC.00989-08.

  52. FDA. What Is the Difference Between FDA-Listed, 510(k) Exempt, Cleared and Approved Medical Devices? [página web]. Silver Spring, MD: U.S. Food and Drug Administration (Administración de Alimentos y Medicamentos de Estados Unidos, actualizada el 5 de enero de 2010). Disponible en: http://goo.gl/iwxgIF [consultada el 24 de enero de 2014].

  53. FDA. OTC (Nonprescription) Drugs [página web]. Silver Spring, MD: U.S. Food and Drug Administration (Administración de Alimentos y Medicamentos de Estados Unidos, actualizada el 24 de enero de 2014). Disponible en: http://goo. gl/ASaOIs [consultada el 24 de enero de 2014].

  54. FDA. FDA Authority Over Cosmetics [página web]. Silver Spring, MD: U.S. Food and Drug Administration (Administración de Alimentos y Medicamentos de Estados Unidos, actualizada el 2 de agosto de 2013). Disponible en: http://goo. gl/434cn5 [consultada el 24 de enero de 2014].

  55. Ravel J, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA 108(suppl 1):4680-4687 (2011); Disponible en: http://dx.doi.org/10.1073/pnas.1002611107.




2020     |     www.medigraphic.com